Central Pain Syndrome Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 24 studies associated with Central Pain Syndrome.
Here is a small sampling of Central Pain Syndrome studies by title:
- Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?
- Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology
- A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis
- An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease.
- Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries
Components of the Central Pain Syndrome Research Dashboard
- Dosing information available for Central Pain Syndrome
- Chemotype guidance for treating Central Pain Syndrome with cannabis
- Synopsis of cannabis research for Central Pain Syndrome
- Individual study details for Central Pain Syndrome
Ready to become a subscriber? Go to our PRICING page.
Central Pain Syndrome Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 24 studies associated with Central Pain Syndrome.
Here is a small sampling of Central Pain Syndrome studies by title:
- Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?
- Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology
- A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis
- An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease.
- Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries
Components of the Central Pain Syndrome Research Dashboard
- Dosing information available for Central Pain Syndrome
- Chemotype guidance for treating Central Pain Syndrome with cannabis
- Synopsis of cannabis research for Central Pain Syndrome
- Individual study details for Central Pain Syndrome
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Central Pain Syndrome
Description of Central Pain Syndrome
Central pain, also known as central neuropathic pain, is a type of chronic pain caused by damage or dysfunction in the central nervous system (CNS), including the brain and spinal cord. There are also significant genetic and environmental predispositions.
Central pain can result from various conditions that affect the CNS, such as multiple sclerosis, stroke, traumatic brain injury, and spinal cord injury. It is characterized by a persistent burning, tingling, or stabbing sensation, often accompanied by sensitivity to touch, temperature, or vibration.
Central pain can be amplified by hyperalgesia or allodynia, which are inappropriate states of over-sensitizing pain and touch. It can also involve other types of painful components, such as peripheral neuropathy. Psychological stressors and cold temperatures can also increase pain.
Central pain can be challenging to treat and may require a combination of medications, physical therapy, and psychological interventions. In addition, it can significantly impact an individual's quality of life, causing sleep disturbances, depression, anxiety, and social isolation.
Therefore, early diagnosis and management of central pain are essential for improving the overall well-being of affected individuals. First-line treatments for centralized pain usually include antidepressants and anticonvulsants.
Disease Classification
Condition: Pain - Central Pain SyndromeDisease Family: Acute or Chronic Pain Disorder
Organ System: Nervous System
ICD-10 Chapter: Diseases of the Nervous System
ICD-10 Code: G89.0
Central Pain Syndrome Symptoms:
Pain originating in the brain or spinal cord (e.g., from stroke, spinal cord trauma, MS), pain can be local or radiate, pain commonly increases with movement or pressure, pain quality (e.g., burning, electric, severe, often chronic). Commonly overlapping chronic pain syndromes like peripheral neuropathy, fibromyalgia, TMDs, IBS, and interstitial cystitis may be increased and contribute their respective features.Also known as:
Dejerine-Roussy syndrome, Myelopathic pain syndrome, Thalamic pain syndromeDrug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
